
Management of inoperable and advanced malignant melanoma has been transformed in recent years by the advent of a number of approaches, including immune checkpoint blockade, small-molecule inhibitors, and adoptive immunotherapy with ex vivo expanded tumor-infiltrating lymphocytes. In this review, we describe...

Skin cutaneous melanoma (SKCM) is a highly aggressive form of skin cancer originating from melanocytes. Its global incidence has risen steadily, with an estimated 325,000 new cases and over 57,000 deaths in 2020, according to the World Health Organization, posing a significant public health challenge...

Birt-Hogg-Dubé syndrome (BHDS) (OMIM#135150) is a rare autosomal dominant tumor-predisposition syndrome caused by pathogenic variants in the FLCN gene encoding the folliculin protein which has been implicated in the regulation of cellular survival, proliferation, and growth by interacting...

Uveal melanoma (UM) is the most common primary intraocular malignancy in adults [1]. Despite advances in primary tumor treatment, survival rates have not improved, largely due to early subclinical micrometastasis at early stages [2]. Recently, Tebentafusp became the first drug showing a survival benefit...

Over the last decade, the increasing global prevalence of melanoma has sparked growing interest in immunotherapies, which show significant potential against this form of skin cancer. This research aims to offer a framework to guide future studies and inspire new research directions. In this study, we...